Skip to main content

Table 6 Relative sensitivity, relative specificity, PPV and NPV of the Cervista HPV HR test and HC2 for detecting CIN3+ within various cytology groups

From: A population-based observational study comparing Cervista and Hybrid Capture 2 methods: improved relative specificity of the Cervista assay by increasing its cut-off

  CERVISTA        
  Relative sensitivity Relative specificity PPV NPV
CIN 3+ % 95% CI % 95% CI % 95% CI % 95% CI
ASC-H, AGUS (Pap III) 80.0% (29.9-98.9) 100.0% (54.6-100) 100.0% (39.6-100) 50.0% (26.7-97.3)
LSIL, HSIL (Pap IIID) 100.0% (80.0-100) 17.5% (7.9-33.4) 37.7% (25.1-52.1) 100.0% (56.1-100)
HSIL, CIS (Pap IVa) 96.6% (87.0-99.4) NA   84.8% (73.4-92.1) NA  
HSIL, CIS, Micro (IVb) 100.0% (19.8-100) NA   100% (19.8-100) NA  
Microinvasive (Pap V) 100.0% (30.1-100) NA   100% (30.1-100) NA  
AGUS+ (≥Pap III) 96.6% (89.7-99.1) 15.7% (7.5-29.1) 66.4% (57.5-74.4) 72.7% (39.3-92.7)
HSIL+ (≥Pap IVa) 96.8% (88.0-99.4) NA   85.9% (75.2-92.7) NA  
  HR HC2        
  Relative sensitivity Relative specificity PPV NPV
CIN 3+ % 95% CI % 95% CI % 95% CI % 95% CI
ASC-H, AGUS (Pap III) 80.0% (29.9-98.9) 100.0% (54.6-100) 100.0% (39.6-100) 50.0% (26.7-97.3)
LSIL, HSIL (Pap IIID) 100.0% (80.0-100) 10.0% (3.3-24.6) 35.7% (23.7-49.7) 100.0% (39.6-100)
HSIL, CIS (Pap IVa) 100.0% (92.3-100) NA   85.3% (74.2-92.3) NA  
HSIL, CIS, Micro (IVb) 100.0% (19.8-100) NA   100% (19.8-100) NA  
Microinvasive (Pap V) 100.0% (30.1-100) NA   100% (30.1-100) NA  
AGUS+ (≥Pap III) 98.9% (92.9-99.9) 9.8% (3.7-22.2) 65.4% (56.6-73.3) 83.3% (36.5-99.1)
HSIL+ (≥Pap IVa) 100.0% (92.8-100) NA   86.3% (75.8-92.9) NA  
  1. +: and higher.